OpGen, Inc. (OPGN)
USD 4.04
(3.86%)
USD 4.04
(3.86%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.41 Million USD | 31.11% |
| 2022 | 2.6 Million USD | -39.45% |
| 2021 | 4.3 Million USD | 2.17% |
| 2020 | 4.21 Million USD | 20.46% |
| 2019 | 3.49 Million USD | 18.75% |
| 2018 | 2.94 Million USD | -8.24% |
| 2017 | 3.21 Million USD | -20.24% |
| 2016 | 4.02 Million USD | 27.49% |
| 2015 | 3.15 Million USD | -23.47% |
| 2014 | 4.12 Million USD | 71.18% |
| 2013 | 2.41 Million USD | -58.45% |
| 2012 | 5.8 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 168.14 Thousand USD | -84.28% |
| 2024 Q2 | 28 Thousand USD | -83.35% |
| 2023 FY | 3.41 Million USD | 31.11% |
| 2023 Q4 | 1.06 Million USD | 53.03% |
| 2023 Q1 | 913.44 Thousand USD | 26.58% |
| 2023 Q2 | 736.13 Thousand USD | -19.41% |
| 2023 Q3 | 699.02 Thousand USD | -5.04% |
| 2022 Q1 | 469.74 Thousand USD | -67.05% |
| 2022 Q4 | 721.63 Thousand USD | 60.82% |
| 2022 FY | 2.6 Million USD | -39.45% |
| 2022 Q3 | 448.71 Thousand USD | -53.61% |
| 2022 Q2 | 967.2 Thousand USD | 105.9% |
| 2021 Q4 | 1.42 Million USD | 15.05% |
| 2021 Q1 | 829.71 Thousand USD | -38.65% |
| 2021 FY | 4.3 Million USD | 2.17% |
| 2021 Q2 | 811.61 Thousand USD | -2.18% |
| 2021 Q3 | 1.23 Million USD | 52.67% |
| 2020 FY | 4.21 Million USD | 20.46% |
| 2020 Q4 | 1.35 Million USD | 27.97% |
| 2020 Q2 | 1.18 Million USD | 92.63% |
| 2020 Q3 | 1.05 Million USD | -11.08% |
| 2020 Q1 | 616.93 Thousand USD | -24.83% |
| 2019 FY | 3.49 Million USD | 18.75% |
| 2019 Q1 | 1.02 Million USD | 34.42% |
| 2019 Q4 | 820.67 Thousand USD | 26.6% |
| 2019 Q3 | 648.22 Thousand USD | -35.79% |
| 2019 Q2 | 1 Million USD | -1.04% |
| 2018 Q4 | 758.95 Thousand USD | 37.44% |
| 2018 Q3 | 552.22 Thousand USD | -30.0% |
| 2018 Q1 | 846.22 Thousand USD | -14.6% |
| 2018 FY | 2.94 Million USD | -8.24% |
| 2018 Q2 | 788.9 Thousand USD | -6.77% |
| 2017 FY | 3.21 Million USD | -20.24% |
| 2017 Q4 | 990.91 Thousand USD | 32.99% |
| 2017 Q3 | 745.11 Thousand USD | 5.96% |
| 2017 Q2 | 703.21 Thousand USD | -8.88% |
| 2017 Q1 | 771.77 Thousand USD | -23.33% |
| 2016 Q1 | 1.07 Million USD | -19.02% |
| 2016 FY | 4.02 Million USD | 27.49% |
| 2016 Q4 | 1 Million USD | 32.5% |
| 2016 Q3 | 759.66 Thousand USD | -35.78% |
| 2016 Q2 | 1.18 Million USD | 9.86% |
| 2015 Q2 | 375.14 Thousand USD | -20.55% |
| 2015 Q1 | 472.2 Thousand USD | -57.92% |
| 2015 Q3 | 980.78 Thousand USD | 161.44% |
| 2015 Q4 | 1.32 Million USD | 35.56% |
| 2015 FY | 3.15 Million USD | -23.47% |
| 2014 Q1 | 1.09 Million USD | 78.11% |
| 2014 Q4 | 1.12 Million USD | 34.42% |
| 2014 Q3 | 834.82 Thousand USD | -22.14% |
| 2014 FY | 4.12 Million USD | 71.18% |
| 2014 Q2 | 1.07 Million USD | -2.28% |
| 2013 Q4 | 616.02 Thousand USD | 0.0% |
| 2013 FY | 2.41 Million USD | -58.45% |
| 2012 FY | 5.8 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aspira Women's Health Inc. | 9.15 Million USD | 62.658% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -34.978% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -9.851% |
| Standard BioTools Inc. | 106.34 Million USD | 96.785% |
| Inotiv, Inc. | 572.42 Million USD | 99.403% |
| Prenetics Global Limited | 21.74 Million USD | 84.278% |
| Neuronetics, Inc. | 71.34 Million USD | 95.209% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 92.534% |
| Castle Biosciences, Inc. | 219.78 Million USD | 98.445% |
| Psychemedics Corporation | 22.09 Million USD | 84.531% |
| RadNet, Inc. | 1.61 Billion USD | 99.789% |
| Exact Sciences Corporation | 2.49 Billion USD | 99.863% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 99.907% |
| iSpecimen Inc. | 9.92 Million USD | 65.57% |
| Exagen Inc. | 52.54 Million USD | 93.495% |
| Bionano Genomics, Inc. | 36.11 Million USD | 90.535% |
| CareDx, Inc | 280.32 Million USD | 98.781% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 312.97 Million USD | 98.908% |
| Guardant Health, Inc. | 563.94 Million USD | 99.394% |
| Biodesix, Inc. | 49.08 Million USD | 93.036% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | 65.015% |
| Precipio, Inc. | 15.19 Million USD | 77.507% |
| Natera, Inc. | 1.08 Billion USD | 99.684% |
| Fulgent Genetics, Inc. | 289.21 Million USD | 98.818% |
| Sera Prognostics, Inc. | 306 Thousand USD | -1017.098% |
| 23andMe Holding Co. | 219.63 Million USD | 98.444% |
| OPKO Health, Inc. | 863.49 Million USD | 99.604% |
| Personalis, Inc. | 73.48 Million USD | 95.348% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 89.061% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | 74.428% |
| T2 Biosystems, Inc. | 7.19 Million USD | 52.477% |
| Neogen Corporation | 924.22 Million USD | 99.63% |
| Myriad Genetics, Inc. | 678.4 Million USD | 99.496% |
| ICON Public Limited Company | 8.12 Billion USD | 99.958% |
| NeoGenomics, Inc. | 591.64 Million USD | 99.422% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 92.534% |
| MDxHealth SA | 70.19 Million USD | 95.13% |
| Prenetics Global Limited | 21.74 Million USD | 84.278% |
| Illumina, Inc. | 4.5 Billion USD | 99.924% |
| DarioHealth Corp. | 20.35 Million USD | 83.204% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 99.819% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -281.731% |
| Trinity Biotech plc | 56.83 Million USD | 93.985% |
| Sotera Health Company | 1.04 Billion USD | 99.674% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -34.978% |